Highest-materiality recent filing
AccuStem submits Medicare coverage application for MSC lung cancer test; enters Novitas review
Submitted local coverage determination to Novitas Solutions for MSC test reimbursement.
Auditor Mazars USA LLP resigns; company seeks replacement
Mazars to resign effective with Q1 2024 10-Q filing, no later than May 31, 2024.
Tiziana Life Sciences purchased 1,337,970 shares of AccuStem common stock at $2.00 per share for gross proceeds of $2,675,940.
On June 5, 2023, Jeff Fensterer, the Chief Operating Officer of AccuStem Sciences Inc. (the “Company”) resigned his position with the Company for personal reasons, effective as of June 16, 2023.
On November 14, 2022, the Board of Directors (the “Board”) of AccuStem Sciences, Inc. (the “Company”) increased the size of the Board to five members and elected Sean McDonald as an independent director, for a term continuing to the Company’s next annual meeting of shareholders, when all directors will be subject to election by shareholders.
On June 20, 2022, Dr. Kunwar Shalubhai notified AccuStem Sciences Inc. (the “Company”) of his decision to resign as a member of the Board, effective immediately.
On March 30, 2022, the Board of Directors of the Company appointed Wendy Blosser, the Company’s Chief Executive Officer as a director to serve on the Board and to hold office until the next annual meeting of stockholders and until her successor is duly elected and qualified
Pursuant to an agreement dated February 18, 2022 (the “Offer Letter”), Wendy Blosser was appointed Chief Executive Officer of AccuStem Sciences, Inc. effective March 4, 2022 (the “Effective Date”).
Max materiality 0.70 · Median 0.50 · Most common event other_material